WORCESTER, Mass. and TORONTO, June 8, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT) reported today that the inaugural meeting of the Scientific Advisory Board (SAB) of its wholly-owned subsidiary, Antigen Express, Inc., for the company's AE37 breast cancer vaccine took place in Dallas, TX on May 19, 2012.
The following distinguished scientists, scholars, and physicians joined representatives of Generex and Antigen Express at the SAB meeting: Dr. Kathy D. Miller, MD (Indiana University School of Medicine Melvin and Bren Simon Cancer Center); Dr. Ian Krop, MD, PhD (Dana-Farber Cancer Institute, Harvard Medical School); Dr. James J. Mule, MD (Moffitt Cancer Centre); Dr. Keith L. Knutson, PhD (Mayo Clinic); Dr. Nuhad Ibrahim, MD (MD Anderson Cancer Center); Dr. Hope S. Rugo, MD (University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center); and, Dr. Samuel Jacobs, MD (National Surgical Adjuvant Breast and Bowel Project (NSABP).
Dr. Eric von Hofe, PhD, President of Antigen Express, reported: "We had a successful and productive inaugural SAB meeting. We are gratified that these key opinion leaders have recognized the potential of our AE37 breast cancer vaccine and joined with us to maximize the potential for clinical and regulatory success. We have received invaluable input regarding our pending transition into a Phase III clinical trial of the vaccine."
Generex is also proud to announce that the following physicians have joined the SAB:
Dr. Samuel Jacobs, MD
Director, Medical Affairs
National Surgical Adjuvant Breast and Bowel Project (NSABP)
Dr. Samuel Jacobs, MD is an emeritus Clinical Professor in the Department of Medicine, University of Pittsburgh School of Medicine, and the Dire
|SOURCE Generex Biotechnology Corporation|
Copyright©2012 PR Newswire.
All rights reserved